Dupilumab Treatment for Prurigo Nodularis and Pruritis
Authors Ross Tanis MD MS, Katalin Ferenczi MD, and B Michael Payette MD MBAB present a case where they demonstrated that treatment of Prurigo Nodularis (PN) with dupilumab significantly decreased pruritis and the size and number of new lesions after 2 months of treatment.
INTRODUCTION
Prurigo nodularis is an intensely pruritic skin disease in which dome-shaped papulonodules result from chroni …
Authors Ross Tanis MD MS, Katalin Ferenczi MD, and B Michael Payette MD MBAB present a case where they demonstrated that treatment of Prurigo Nodularis (PN) with dupilumab significantly decreased pruritis and the size and number of new lesions after 2 months of treatment.
INTRODUCTION
Prurigo nodularis is an intensely pruritic skin disease in which dome-shaped papulonodules result from chroni … Continue reading "Dupilumab Treatment for Prurigo Nodularis and Pruritis"
Welcome to the next delivery of our series, Therapeutic Cheat Sheet, wherein we take a deep dive into the literature and guidelines to give you a quick reference on the use of new or complex therapies. This series will become your go-to for information about dosing, potential interactions and laboratory monitoring, just to name a few. Next up: Cyclosporine.
Cyclosporine is a versatile and v … 
Derm In-Review Advisory Council Member, Dr. Ramya Kollipara, searched dermatology journals so that you don’t have to! She reports on important take-aways from different medical journals for the months of January, February, and March of 2018. Find study tools and more like this at Derm In-Review.
It is key to keep in mind that “important” is subjective and what is contained in this revie … 
Have you received the latest issue of the JDD? Below are Journal of Drugs in Dermatology highlights and editor picks for the October issue!
Consensus Recommendations on Adjunctive Topical Management of Atopic Dermatitis provides an overview of AD, summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with … 
PART 1
The well-known Dr. Gil Yosipovitch, Professor of Dermatology at the University of Miami Miller School of Medicine and Director of the Miami Itch Center, recently lectured on various aspects of itch at the 2018 ODAC meeting. He has asked his two research fellows to write on the topic for Next Steps in Dermatology. This is the first article in a 2-part series about itch.
A … 